Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
about
Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modelingImproving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysPiZ mouse liver accumulates polyubiquitin conjugates that associate with catalytically active 26S proteasomesProteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome StructureCellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate.Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity.
P2860
Q27334339-30743427-73AF-459A-A7BE-5D833867BA40Q28077848-23D80E8C-1C26-4029-A58E-5DA6497943DBQ35247414-B65A78C9-3C19-4010-B0BE-54A4E2DA8B1DQ35408665-8EEFCF91-2E99-4442-8C99-35C4961E185AQ35895152-0E75CCF8-E535-4A18-A536-3C3228051B20Q36833345-3D5B59B7-6162-45DF-8723-43ECCD4202F8Q38757895-16B00C6B-3D95-4191-9563-3CE2453B4573Q38842522-4BCEBB9D-2E77-471F-A1BE-DC2EE78A353CQ38932086-EA091EC2-3928-479C-B921-8EF71DE4E043Q41607725-5BDFA6BA-EED2-41F6-9DE6-DDC1A9D881E5Q47096168-3D209B2C-EE1B-4916-AB81-2D95F24DFABAQ47102326-49970BCD-7717-49ED-AB2D-35983EE6A2C9Q47987649-AAAD021E-65C5-4020-8002-E45B6823D075Q52597827-BCBEBC11-5155-4B49-BD6E-98B4EB04DBBBQ54998639-DCFADC05-E376-4A44-AD9E-5405327B1086Q55476988-6F2D124D-DB23-4404-BE19-ECC065F0C6C5
P2860
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Molecular basis of differentia ...... lus treatment with bortezomib.
@ast
Molecular basis of differentia ...... lus treatment with bortezomib.
@en
Molecular basis of differentia ...... lus treatment with bortezomib.
@nl
type
label
Molecular basis of differentia ...... lus treatment with bortezomib.
@ast
Molecular basis of differentia ...... lus treatment with bortezomib.
@en
Molecular basis of differentia ...... lus treatment with bortezomib.
@nl
prefLabel
Molecular basis of differentia ...... lus treatment with bortezomib.
@ast
Molecular basis of differentia ...... lus treatment with bortezomib.
@en
Molecular basis of differentia ...... lus treatment with bortezomib.
@nl
P2093
P2860
P1433
P1476
Molecular basis of differentia ...... lus treatment with bortezomib.
@en
P2093
Alan Eastman
Alexei F Kisselev
Ayrton L Goddard
Marcella M Lucas
Michael Screen
Tamer B Shabaneh
P2860
P304
P356
10.1371/JOURNAL.PONE.0056132
P407
P577
2013-02-27T00:00:00Z